Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 - Evaxion (NASDAQ:EVAX)
Presentation will cover two-year clinical efficacy, immunogenicity and safety data Data will be presented at an oral session on October 17, 2025, followed by a webinar on October 22, 2025, providing further insights into the clinical findings
How this was made

The 30-second read
Why it matters
Positive clinical data could validate the company's approach and boost stock value.
Market read
High relevance for biotech investors and those interested in innovative cancer treatments.
What to watch
Potential delays in data presentation or regulatory hurdles could impact stock performance.
Background
Evaxion is developing AI-designed personalized cancer vaccines, with EVX-01 being a leading candidate.
Ticker impact
High relevance due to upcoming presentation of clinical data at a major oncology conference.
Potential short-term increase in stock price ahead of data release; long-term impact depends on clinical outcomes.
The presentation of two-year efficacy, immunogenicity, and safety data is likely to boost investor confidence, especially if results are favorable. However, as the data is upcoming, actual impact depends on the findings.
Market effects
Potential positive impact on biotech and immunotherapy sectors.
Likely to influence biotech stocks in North America and Europe.
Moderate; primarily relevant to oncology and biotech investors.
Counterpoint
Data may not meet expectations, leading to volatility or a decline in EVAX stock.
Key entities
- CompanyEvaxion Biotech
Biotech firm specializing in AI-driven immunotherapies.
- ProductEVX-01
Personalized cancer vaccine in clinical development.
- EventESMO Congress 2025
Major oncology conference where data will be presented.


